ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS

    Author microcapwatchPosted on Categories BiotechTags , , , , , , , , , , , , , ,

    <br /> ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS<br />

    PR Newswire


    SOUTH SAN FRANCISCO

    ,


    California




    and

    VANCOUVER, Canada

    ,

    March 9, 2022

    /PRNewswire/ – ESSA Pharma Inc. (”

    ESSA

    ” or the ”

    Company

    “) (NASDAQ: EPIX), a clinical stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held virtually on

    March 9, 2022

    (the ”

    Meeting

    “).

    At the Meeting, the shareholders of the Company (the ”

    Shareholders

    “) resolved to set the number of directors of the Company at eight and re-elected to the board of directors, by ordinary resolution passed by ballot vote,

    David R. Parkinson

    ,

    Richard M. Glickman

    ,

    Gary Sollis

    ,

    Franklin M. Berger

    ,

    Scott Requadt

    ,

    Marella Thorell

    ,

    Alex Martin

    , and

    Sandy Zweifach

    to serve in office until the next annual meeting or until their successors are duly elected or appointed. Detailed results of the voting in respect of the election of directors are as follows:



    Nominee



    Votes For



    % Votes For



    Votes Withheld



    % Votes Withheld


    David R. Parkinson


    29,377,984


    99.90%


    28,772


    0.10%


    Richard M. Glickman


    29,253,929


    99.48%


    152,827


    0.52%


    Gary Sollis


    28,596,127


    97.24%


    810,629


    2.76%


    Franklin M. Berger


    20,684,413


    70.34%


    8,722,343


    29.66%


    Scott Requadt


    29,369,580


    99.87%


    37,176


    0.13%


    Marella Thorell


    28,847,371


    98.10%


    559,385


    1.90%


    Alex Martin


    26,914,856


    91.53%


    2,491,900


    8.47%


    Sandy Zweifach


    29,387,996


    99.94%


    18,760


    0.06%

    At the Meeting, the Shareholders also approved: (i) the re-appointment of Davidson & Company LLP, Chartered Professional Accountants, as auditors of the Company; (ii) an amendment to the Company’s omnibus incentive plan (as amended, the ”

    Amended Omnibus Plan

    “) to increase the number of common shares of the Company reserved and available for issuance under the Amended Omnibus Plan; (iii) on a non-binding advisory basis, the compensation of the Company’s named executive officers; and (iv) on a non-binding advisory basis, “one year” as the frequency of solicitation for advisory shareholder approval of executive compensation.


    About ESSA Pharma Inc.

    ESSA is a clinical-stage pharmaceutical company focused on developing novel and proprietary therapies for the treatment of patients with prostate cancer. For more information, please visit

    www.essapharma.com

    and follow us on Twitter under @ESSAPharma.

    Cision
    View original content:

    https://www.prnewswire.com/news-releases/essa-pharma-inc-reports-results-of-annual-general-meeting-of-shareholders-301499745.html

    SOURCE ESSA Pharma Inc

    PR Newswire
    March 9, 2022 – 8:34 PM PST